Prostate Cancer Clinical Trials in Baltimore

Showing 221-240 of 388 trials

Safety Study of MGA271 in Refractory Cancer

NCT01391143

The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.

Prostate CancerMelanomaRenal Cell Carcinoma+4 more

MacroGenics179 participantsStarted Jul 2011

Los Angeles, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +9 more locations

COMPLETEDPhase 2< 1 mile

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

NCT02601014

This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7). Tumor cells expressing AR-V7 has been shown to be resistant to hormone therapy and some chemotherapy in patients with prostate cancer. Biomarker-driven therapy, such as nivolumab and ipilimumab, may work by blocking key biomarkers or proteins that help tumor cells to escape the immune system surveillance and this may help the immune system to kill tumor cells that express AR-V7.

Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins32 participantsStarted Mar 2016

Baltimore, Maryland, United States

Safety Study of MGA271 in Refractory Cancer

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Prostate Cancer Trials in Other Cities

Music Listening as a Postanesthesia Care Unit (PACU) Nursing Intervention

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

A Survivorship Care Plan and Embedded Navigation Tool

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Ketogenic Diet and Prostate Cancer Surveillance Pilot

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Oral Calcitriol With Ketoconazole in CRPC

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

Perioperative Post-Prostatectomy Incontinence Home Telehealth Program

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Other Conditions in Baltimore